Objective To evaluate the correlation of autoantibodies and clinical significance in patients with primary biliary cirrhosis (PBC). Methods A total of 48 patients with PBC, 182 subjects without PBC and 50 healthy controls were employed in this study. Sera from all participants were examined for the presence of PBC-related autoantibodies, including AMA-M2, GP210, SP100, ANA, ds-DNA, AMA, SMA and ACYA with the methods of Western blot and indirect immunofluorescence. The results and hepatic clinical parameters were retrospectively analyzed. Results The positive rates of ANA, AMA, SMA, ACYA and ds-DNA were-M. 7% , 93. 8% , 12.5% , 79. 2% and 2.1 % respectively in PBC group, which were statistically significant compared with control group (except ds-DNA, P<0.01) and non-PBC group (only including AMA and ACYA, P < 0. 01). The positive rates of AMA-M2, GP210 and SP100 were 68. 8% , 41. 7% and 16.7% respectively in PBC group, which were both statistically significant with non-PBC group and control group. Conclusion Utilization of AMA-M2, GP210, SP100 and AMA autoantibodies as the combined diagnostic markers lead to improved detection of PBC.%目的 探讨原发性胆汁性肝硬化(PBC)患者自身抗体相关性及临床意义.方法 采用免疫印迹法及间接免疫荧光法检测48例PBC、182例非PBC患者及50例健康对照抗线粒体抗体M2亚型(AMA-M2)、抗核包膜蛋白抗体(GP210)、抗核多点抗体(SP100)、抗核抗体(ANA)、抗双链DNA抗体(ds-DNA)、抗线粒体抗体(AMA)、抗平滑肌抗体(SMA)及抗细胞质抗体(ACYA)等自身抗体并观察其临床评估指标,对其结果进行回顾性分析.结果 48例PBC患者ANA、AMA、SMA、ACYA及ds-DNA抗体阳性率分别为41.7％、93.8％、12.5％、79.2％和2.1％:ANA、AMA、SMA和ACYA与对照组比较,P均＜0.01；AMA和ACYA与非PBC组比较,P均＜0.01.48例PBC患者AMA-M2、GP210及SP100抗体阳性率分别为68.8％、41.7％和16.7％；与非PBC组和对照组比较,P均＜0.01.结论 检测AMA-M2、GP210、SP100和AMA等自身抗体对PBC的诊断、鉴别诊断、治疗及预后具有重要的作用,可提高PBC诊疗水平.
展开▼
